Coding the Deadly COVID
Christine Geiger, MA, RHIA, CCS, CRC
November 25, 2024
While it is not in the news on a daily basis any longer, COVID has not gone away. Since the start of the pandemic, we
They are both mammals, they share some identical genes, but they should not share the same drug: ivermectin.
What is ivermectin? Ivermectin is an avermectin – a type of naturally occurring drug, by way of fermentation – discovered through culture of the fungus Streptomyces avermitilis in 1967. It is an effective anti-parasitic drug whose discoverers won the Nobel Prize in 2015.
Ivermectin has been and is currently used to treat humans and animals for pathogen infestation or infection, and is part of the World Health Organization’s (WHO’s) Model List of Essential Medicines. Ivermectin may stop diseases like onchocerciasis or river blindness, an illness caused by helminths that damage capillaries of the eye; lymphatic filariasis, with accumulation of Wucheria worms in lymph vessels or glands; and scabies, a skin irritation caused by Sarcoptes mites. It may be administered by tablet, ointment, or injection in appropriate concentrations.
In our crazy COVID-19 times, its use against viral infection has been tested in humans, and the drug is currently being utilized to treat COVID-positive patients in 24 developing countries, including India, Peru, and others.
“But SARS-CoV-2 is a virus, not a parasite, correct?” one might ask. “Why would one think a drug which affects growth of parasites could also inhibit growth of viruses?”
Viruses and parasites are different types of microbes. Viruses are considered non-living, as they require a host to reproduce. Parasites are classified in the same grouping as humans: eukaryotes. They may function alone, but thrive on nutrients and housing from a host. Both viruses and parasites may elicit a similar outcome from infection in the human body, namely clumping of blood cells, or microvascular occlusion.
The commonality of disease sequelae prompted investigators to question if ivermectin might prove useful for treatment of COVID-19 patients. The alteration in blood clotting may damage the lining, or endothelium, of capillaries. When damaged vessels surround the alveoli or functional units for gas exchange in lungs, victims are deprived of oxygen, hence the need for ventilators in severe COVID-19 cases.
As of July 2021, the National Institutes of Health (NIH) followed 16 of 55 studies for assessment of ivermectin’s effects on COVID-19 cases. It is thought that ivermectin interferes with one or more of 20 identified levels for infection, level one being binding virus to host cells (blocked by steric hindrance?), through host inflammatory responses, thus stopping viral progression.
Some studies have been discounted for small sample size, non-randomization of subjects, or incomplete follow-up. Dr. Omura, the ivermectin Nobel co-laureate, with colleagues, published a review with data showing a sizable decrease in morbidity and mortality for human COVID-19 patients treated with ivermectin.
Due to fervent wishes to stay safe, people have taken drugs intended for animal use. The Food and Drug Administration (FDA) recently tweeted, “you are not a horse. You are not a cow. C’mon ya’ll. Stop it.” The formulations and dosages for animal medications are NOT appropriate for humans. The ivermectin injection for cattle contains polyethylene glycol (PEG), a.k.a. antifreeze.
Ivermectin holds promise for SARS treatment: it has been approved, is inexpensive, and could be repurposed. But the best primary prevention for COVID-19 remains the Pfizer, Moderna, or J&J vaccine!
Programming Note: Listen to Julia Brodt report this story live today during Talk Ten Tuesdays, 10 Eastern.
While it is not in the news on a daily basis any longer, COVID has not gone away. Since the start of the pandemic, we
The Centers for Medicare & Medicaid Services (CMS) has released a report on the Acute Hospital Care at Home (AHCAH) initiative, a program allowing select
Please log in to your account to comment on this article.
Prepare your organization for the 2025 OPPS updates with expert insights from Tiffani Bouchard, CCS, CRCR, a Revenue Integrity Professional with over 30 years of experience. This webcast will address critical challenges in charge capture and coding, providing clarity on APC policies, C-APC packaging, exclusions, and payer-specific requirements. Attendees will learn actionable strategies to ensure compliance, optimize reimbursement, and mitigate risks of claim denials. Gain the knowledge needed to implement updates effectively, educate your team, and maintain seamless revenue cycle operations in the face of evolving OPPS complexities.
Join Beth Wolf, MD, CPC, CCDS, for an in-depth webcast on the FY2025 spinal fusion MS-DRG updates. Discover key changes in DRG classification, understand impacts on documentation and CMI, and learn strategies to ensure compliance.
Join Angela Comfort, DBA, MBA, RHIA, CDIP, CCS, CCS-P, as she presents effective strategies to strengthen collaboration between CDI, coding, and quality departments in acute care hospitals. Angela will also share guidance on implementing cross-departmental meetings, using shared KPIs, and engaging leadership to foster a culture of collaboration. Attendees will gain actionable tools to optimize documentation accuracy, elevate quality metrics, and drive a unified approach to healthcare goals, ultimately enhancing both patient outcomes and organizational performance.
Optimize your outpatient clinical documentation and gain comprehensive knowledge from foundational practices to advanced technologies, ensuring improved patient care and organizational and financial success. This webcast bundle provides a holistic approach to outpatient CDI, empowering you to implement best practices from the ground up and leverage advanced strategies for superior results. You will gain actionable insights to improve documentation quality, patient care, compliance, and financial outcomes.
The 2025 Medicare Physician Fee Schedule brings significant changes to payment rates, coverage, and coding for physician services, impacting practices nationwide. Join Stanley Nachimson, MS., as he provides a comprehensive guide to understanding these updates, offering actionable insights on new Medicare-covered services, revised coding rules, and payment policies effective January 1. Learn how to adapt your practices to maintain compliance, maximize reimbursement, and plan for revenue in 2025. Whether you’re a physician, coder, or financial staff member, this session equips you with the tools to navigate Medicare’s evolving requirements confidently and efficiently.
Dr. Ronald Hirsch provides critical details on the new Medicare Appeal Process for Status Changes for patients whose status changes during their hospital stay. He also delves into other scenarios of hospital patients receiving custodial care or medically unnecessary services where patient notifications may be needed along with the processes necessary to ensure compliance with state and federal guidance.
Healthcare organizations face complex regulatory requirements under the No Surprises Act and Price Transparency rules. These policies mandate extensive fee disclosures across settings, and confusion is widespread—many hospitals remain unaware they must post every contracted rate. Non-compliance could lead to costly penalties, financial loss, and legal risks. Join David M. Glaser Esq. as he shows you how to navigate these regulations effectively.
Protect your facility from unwanted audits! Join Becky Jacobsen, BSN, RN, MBS, CCS-P, CPC, CPEDC, CBCS, CEMC, and take a deep dive into both the CMS and AMA guidelines for reporting post operative pain blocks. You’ll learn how to determine if the nerve block is separately codable with real life examples for better understanding. Becky will also cover how to evaluate whether documentation supports medical necessity, offer recommendations for stronger documentation practices, and provide guidance on educating providers about documentation requirements. She’ll include a discussion of appropriate modifier and diagnosis coding assignment so that you can be confident that your billing of post operative pain blocks is fully supported and compliant.
Copyright © 2025 ICD10monitor. Powered by MedLearn Media.
Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more
Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
